Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


CHMP positive for Vabysmo (faricimab) marketing authorisation to include the treatment of visual impairment due to macular edema secondary to retinal vein occlusion – Roche

Written by | 3 Jul 2024

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the Vabysmo (faricimab) marketing… read more.

New long-term data for Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) – Genentech/Roche

Written by | 6 Feb 2024

Genentech, a member of the Roche Group announced new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to… read more.

New two-year data for Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two causes of vision loss – Genentech/Roche

Written by | 9 Apr 2022

Genentech, announced that new two-year data from its Phase III studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.